Compare · EVMN vs MRK
EVMN vs MRK
Side-by-side comparison of Evommune Inc. (EVMN) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $329.65B, about 1133.2x EVMN ($290.9M).
- MRK has been more active in the news (25 items in the past 4 weeks vs 24 for EVMN).
- MRK has more recent analyst coverage (25 ratings vs 15 for EVMN).
- Company
- Evommune Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- $290.9M
- $329.65B
- 1M return
- -
- -9.16%
- 1Y return
- -
- +36.81%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 24
- 25
- Recent ratings
- 15
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest EVMN
- Director Arthur S Kirsch returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Director David E Cohen returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Director Benjamin F Mcgraw III returned 53,633 stock options to the company and was granted 53,633 stock options (SEC Form 4)
- Chief of Dev. Operations Janice Suzann Drew returned 305,166 stock options to the company and was granted 305,166 stock options (SEC Form 4)
- Chief Scientific Officer Jeegar Pravinkumar Patel returned 248,934 stock options to the company and was granted 248,934 stock options (SEC Form 4)
- Chief Financial Officer Kyle Carver returned 378,354 stock options to the company and was granted 378,354 stock options (SEC Form 4)
- Chief Business & Legal Officer Gregory S. Moss returned 408,775 stock options to the company and was granted 408,775 stock options (SEC Form 4)
- Chief Medical Officer Eugene Bauer returned 151,117 stock options to the company and was granted 151,117 stock options (SEC Form 4)
- President & CEO Luis C. Pena returned 1,088,261 stock options to the company and was granted 1,088,261 stock options (SEC Form 4)
- SEC Form 424B3 filed by Evommune Inc.
Latest MRK
- Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
- Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Merck & Company Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
- Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- Merck Announces First-Quarter 2027 Dividend
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London